Core Viewpoint - West Point Pharmaceutical (301130.SZ) has announced its existing products, including a mature anti-influenza drug, compound acetaminophen and amantadine capsules, and an antiviral tablet expected to be approved for market in 2025 for treating upper respiratory infections and influenza [1] Group 1 - The company has a mature anti-influenza product, compound acetaminophen and amantadine capsules [1] - An antiviral tablet is anticipated to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [1] - The research project on "the intervention effect of Ruixiangsu on mouse models of human diseases" has shown safety and efficacy results for Ruixiangsu in treating viral pneumonia [1] Group 2 - The company has obtained a patent for "the application of Ruixiangsu in the preparation of drugs for treating viral pneumonia" [1]

Core Viewpoint - The company has recently obtained an invention patent certificate for the synthesis method of a core product, which signifies a strategic enhancement of its technological capabilities and intellectual property protection [1][2]. Group 1: Patent Acquisition - The company has received an invention patent certificate from the National Intellectual Property Administration of China for a synthesis method of Rhizoma Anemones [1]. - The synthesis method involves using gallic acid and malic acid as raw materials, with concentrated sulfuric acid as a condensation catalyst, achieving a product yield of over 90% and purity of up to 99% [1]. Group 2: Strategic Implications - The acquisition of this patent reflects not only a technological advancement but also a strategic move to strengthen core technologies and lay a foundation for future development [2]. - The company now holds two patents related to the synthesis process of Rhizoma Anemones, which will enhance its core competitiveness in technological innovation and support the development of this key product [2].

Core Points - The company has recently obtained an invention patent certificate from the National Intellectual Property Administration of the People's Republic of China [1] - The patent is titled "A Synthesis Method of Ruscogenin" and has a patent number of 8338136 [1] - The patent application date was July 28, 2025, and the authorization announcement date was October 10, 2025 [1] - The patent is owned by Jilin Xidian Pharmaceutical Technology Development Co., Ltd., and has a validity period of 20 years [1]